Related Experiment Video
Updated: May 17, 2026

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
Published on: June 28, 2018
A novel evolutionarily conserved element is a general transcriptional repressor of p21WAF¹/CIP¹
Weiguo Xu1, Qi Zhu, Zhenghua Wu
1School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
The effective induction of p21(WAF1/CIP1/Cdkn1a) (p21) expression in p53-negative cancer cells is an important avenue in cancer management. We investigated the ability of various common chemotherapeutic drugs to induce p21 expression in p53-negative cancer cells and showed that the induction of p21 expression by oxaliplatin is caused by the derepression of a previously unrecognized negative regulatory element with a Sp1/Sp3 palindrome sequence core at -216 to -236 of the p21 proximal promoter. Electrophoretic mobility shift and antibody super-shift assays confirmed the specific binding of Sp1/Sp3, and showed that the oxaliplatin-mediated derepression of p21 transcription was associated with an increased Sp1/Sp3 phosphorylation and binding affinity to the oxaliplatin-responsive element. A search of the ENCODE database for vertebrate-conserved genomic elements identified the Sp1/Sp3 palindrome element as the only vertebrate-conserved element within the 500-bp proximal p21 promoter region, indicating its fundamental importance. In in vivo competition assays, transfected synthetic Sp1/Sp3 palindrome elements derepressed the cotransfected or endogenous p21 promoter in a dosage-dependent manner. This derepression was not seen in oxaliplatin-treated cells, suggesting that the exogenous Sp1/Sp3 palindrome and oxaliplatin had the same downstream signaling target. Taken together, our results revealed, for the first time, this evolutionarily conserved Sp1/Sp3 palindrome element in the proximal p21 promoter that serves as a regulatory repressor to maintain p21 basal level expression.
Insights
Oxaliplatin effectively induces p21 expression in p53-negative cancer cells by derepressing a conserved Sp1/Sp3 element in the p21 promoter. This finding offers a new strategy for cancer management by targeting this regulatory repressor.
Area of Science:
- Molecular Biology
- Cancer Research
- Genomics
Background:
- Inducing p21 (WAF1/CIP1/Cdkn1a) expression is crucial for managing p53-negative cancers.
- The precise mechanisms regulating p21 expression in these cells remain incompletely understood.
Purpose of the Study:
- To investigate how common chemotherapeutic drugs, specifically oxaliplatin, induce p21 expression in p53-negative cancer cells.
- To identify and characterize the regulatory elements and molecular mechanisms involved in oxaliplatin-mediated p21 induction.
Main Methods:
- Utilized electrophoretic mobility shift and antibody super-shift assays to confirm Sp1/Sp3 binding to the p21 promoter.
- Analyzed the ENCODE database to identify conserved regulatory elements within the p21 promoter.
- Performed in vivo competition assays to assess the function of the identified Sp1/Sp3 palindrome element.
Main Results:
- Oxaliplatin induces p21 expression by derepressing a novel negative regulatory element containing an Sp1/Sp3 palindrome in the p21 proximal promoter (-216 to -236).
- Oxaliplatin treatment increases Sp1/Sp3 phosphorylation and binding affinity to this element, leading to p21 transcriptional derepression.
- The Sp1/Sp3 palindrome is the only vertebrate-conserved element in the proximal p21 promoter, highlighting its functional significance.
Conclusions:
- A conserved Sp1/Sp3 palindrome element in the p21 promoter acts as a repressor of basal p21 expression.
- Oxaliplatin overcomes this repression through enhanced Sp1/Sp3 activity, providing a novel therapeutic target for p53-negative cancers.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Co-activators and Co-repressors
Co-activators and Co-repressors
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway

